KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBITDA: 2020-2025

Historic EBITDA for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' EBITDA fell 79.67% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 88.58%. This contributed to the annual value of -$479.0 million for FY2024, which is 36.83% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its EBITDA stood at -$172.2 million for Q3 2025, which was up 2.28% from -$176.2 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' EBITDA peaked at -$30.5 million during Q1 2021, and registered a low of -$191.4 million during Q1 2025.
  • For the 3-year period, Recursion Pharmaceuticals' EBITDA averaged around -$122.0 million, with its median value being -$97.5 million (2024).
  • Per our database at Business Quant, Recursion Pharmaceuticals' EBITDA plummeted by 153.94% in 2021 and then increased by 6.12% in 2022.
  • Recursion Pharmaceuticals' EBITDA (Quarterly) stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then crashed by 62.23% to -$98.9 million in 2023, then slumped by 85.76% to -$183.8 million in 2024, then tumbled by 79.67% to -$172.2 million in 2025.
  • Its EBITDA was -$172.2 million in Q3 2025, compared to -$176.2 million in Q2 2025 and -$191.4 million in Q1 2025.